In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses

Annals of Neurology

Volumn 59, Issue 1, 2006, Pages 13-20

  Kuhl, David E ^a,c   Koeppe, Robert A ^a   Snyder, Scott E ^a   Minoshima, Satoshi ^a,b   Frey, Kirk A ^a   Kilbourn, Michael R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PIPERIDINYL N BUTYRATE C 11; ACETYLCHOLINE; ACETYLCHOLINESTERASE; CARBON 11; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; N METHYLPIPERIDIN 4 YL PROPIONATE C 11; PHYSOSTIGMINE; PIPERIDINE DERIVATIVE; RIVASTIGMINE; TRACER; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; CHOLINESTERASE INHIBITION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HYDROLYSIS; IN VIVO STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SYNAPSE;

ACETYLCHOLINESTERASE; ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BUTYRYLCHOLINESTERASE; CARBON RADIOISOTOPES; CEREBRAL CORTEX; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; PHYSOSTIGMINE; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; SYNAPSES;

EID: 29944441736     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20672     Document Type: Article

References (49)

1. Mesulam MM, Geula C. Overlap between acetylcholinesteraserich and choline acetylttansferse-positive (cholinergic) axons in human cerebral cortex. Brain Res 1992;577:112-120.
2. Wright CI, Geula C, Mesulam MM. Neuroglial cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability. Ann Neurol 1993;34:373-384.
3. Mesulam MM, Geula C. Butyrylcholinesterase activity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 1994;36:722-727.
4. Silver A. The biology of cholinesterases. Amsterdam: Elsevier, Amsterdam 1974.
5. Weinstock M. Selectivity of cholinesterase inhibition. Clinical implications for the treatment of Alzheimer's disease. CNS Drugs 1999;12:307-323.
6. Giacobini E. Cholinesterase inhibitors: from the Calabar bean to Alzheimer therapy. In: Giacobini E, ed. Cholinesterases and cholinesterase inhibits. London: Martin Dunitz Ltd, 2000:181-226.
7. Giacobini E, Spiegel R, Enz A, et al. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. J Neurol Transm 2002;109:1053-1065.
8. Ballard CG. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur Neurol 2002;47:64-70.
9. Mesulam MM, Guillozet A, Shaw P, Quinn B. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis 2002;9:88-93.
10. Darvesh S, Hopkins DA, Geula C. Neurobiology of butyryl-cholinesterase. Neurosci Nat Rev 2003;4:131-138.
11. Geula C, Darvesh S. Butyrylcholinesterase, cholinergic neurotransmission and the pathology of Alzheimer's disease. Drugs Today 2004;40:711-721.
12. Davies P, Maloney AJR. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976;2:1403.
13. Coyle JT, Price DL, De Long MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983;219:1184-1190.
14. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999;66:137-147.
15. Darreh-Shori T, Almkvist O, Guan ZZ, et al. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 2002;59:563-572.
16. Liston DR, Nielsen JA, Villalobos A, et al. Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease. Eur J Pharmacol 2004;486:9-17.
17. Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J. Cholinesterase inhibitors used in the treatment of Alzheimer's disease. The relationship between pharmacological effects and clinical efficacy. Drugs Aging 2004;21:453-478.
18. Imbimbo BP. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. CNS Drugs 2001;15:375-390.
19. Perry EK, Perry RH, Blessed G, Tomlinson BE. Changes in brain cholinesterase in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 1978;4:273-277.
20. Geula C, Mesulam MM. Special properties of cholinesterases in the cerebral cortex of Alzheimer's disease. Brain Res 1989;498:185-189.
21. Arendt T, Bruckner MK, Lange M, Bigl V. Changes in acetylcholinesterase and buryrylcholinesterase in Alzheimer's disease resemble embryonic development: a study of molecular forms. Neurochem Int 1992;21:381-396.
22. Gomez-Ramos P, Bouras C, Moran MA. Ultrastructural localization of butyrylcholinesterase on neurofibrillary degeneration sites in the brains of aged and Alzheimer's disease patients. Brain Res 1994;640:17-24.
23. Geula C, Mesulam MM. Cholinesterases and the pathology of Alzheimer disease. Alzheimer Dis Assoc Disord 1995;9:23-28.
24. Snyder SE, Gunupudi N, Sherman PS, et al. Radiolabeled cholinesterase substrates: in vitro methods for determining structure-activity relationships and identification of a positron emission tomography radiopharmaceutical for in vivo measurement of butyrylcholinesterase activity. J Cereb Blood Flow Metab 2001;21:132-143.
25. Irie T, Fukushi K, Akimoro Y, et al. Design and evaluation of radioactive acetylcholine analogs of mapping brain acetylcholinesterase (AChE) in vivo. Nucl Med Biol 1994;21:801-808.
26. 11C] PMP). Synapse 1996;22:123-131.
27. 11C] PMP) for in vivo measurements of acetylcholinesterase activity. Nucl Med Biol 1998;25:751-754.
28. Kuhl DE, Koeppe RA, Minoshima S, et al. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology 1999;52:691-699.
29. 11C] methylpiperidin-4-yl propionate: alternatives for analysis of an irreversible PET tracer for measurement of acetylcholinesterase activity in human brain. J Cereb Blood How Metab 1999;19:1150-1163.
30. Kuhl DE, Minoshima S, Frey KA, et al. Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol 2000;48:391-395.
31. 11C-methyl-4-piperidinyl n-butyrate in humans: an imaging agent for in vivo assessment of butyrylcholinesterase activity with PET. J Nucl Med 2004;45:2032-2039.
32. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
33. Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-572.
34. Folstein M, Folstein SE, McHugh PR. "Mini Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
35. 11C] methylpiperidine esters as acetylcholinesterase substrates: an in vivo structure-activity study. Nucl Med Biol 1998;25:755-760.
36. 18F] PDG. J Nucl Med 1995;36:1238-1248.
37. Giacobini E. Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease? Drugs Aging 2001;18:891-898.
38. Darvesh S, Walsh R, Kumar R, et al. Inhibition of human cholinesterases by drugs used to treat Alzheimer Disease. Alzheimer Dis Assoc Disord 2003;17:117-126.
39. Atack JR, Perry EK, Bonham JR, et al. Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system. J Neurochem 1986;47:263-277.
40. Mesulam MM, Guillozet A, Shaw P, et al. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience 2002;110:627-639.
41. Guillozet AL, Smiley JF, Mash DC, Mesulam MM. Butyrylcholinesterase in the life cycle of amyloid plaques. Ann Neurol 1997;42:909-918.
42. Beach TG, Kuo YM, Spiegel K, et al. The cholinergic deficit coincides with A-beta deposition at the earliest histopathologic stages of Alzheimer disease. J Neuropathol Exp Neurol 2000;59:308-313.
43. Kaasinen V, Nagren K, Jarvenpaa T, et al. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J Clin Psychopharmacol 2002;22:615-620.
44. Shinotoh H, Fukushi K, Nagatsuka S, Irie T. Acetylcholinesterase imaging: its use in therapy evaluation and drug design. Curr Pharm Des 2004;10:1505-1517.
45. Bohnen NI, Kaufer DI, Hendrickson R, et al. Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2005;76:315-319.
46. Massoulie J. The origin of the molecular diversity and functional anchoring of cholinesterases. Neurosignals 2002;11:130-143.
47. Atack JR, Perry EK, Bonham JR, et al. Molecular forms of acetylcholinesterase in senile dementia of Alzheimer type: selective loss of intermediate (10S) form. Neurosci Lett 1983;40:199-204.
48. Wilkinson DG, Passmore AP, Bullick R, et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract 2002;56:441-446.
49. Lopez-Pousa S, Turon-Estrada A, Garre-Olmo J, et al. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period. Dement Geriatr Cogn Disord 2005;19:189-195.